Press Releases
Imago BioSciences, Inc. Announces Proposed Initial Public Offering of Common Stock
Jul 12, 2021
Imago BioSciences’ Bomedemstat Demonstrates Continued Encouraging Clinical Activity in Phase 2 Data for Treatment of Essential Thrombocythemia and Myelofibrosis at EHA 2021 Virtual Congress
Jun 11, 2021
Imago BioSciences Appoints Wan-Jen Hong, M.D., as Chief Medical Officer
Jun 03, 2021
Imago BioSciences to Present Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at 2021 European Hematology Association Virtual Congress
May 21, 2021
Imago BioSciences to Participate in Upcoming Investor Conferences
Feb 09, 2021
Displaying 26 - 30 of 60